Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04903132

Cellular Senescence and COVID-19 Long-Hauler Syndrome

The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

About this study

Assays for cellular senescence markers, SASP factors, inflammatory mediators, pro-fibrotic factors, and auto-antibodies in blood and urine will be conducted in patients who provide informed consent. Data will be related to subject age, date of COVID-19 infection, severity of that infection, current Long-Hauler Syndrome symptoms), physical examination findings, underlying conditions, and laboratory data. To understand if an association between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than controls in this pilot study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Longhauler's Cohort -

Inclusion criteria

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject or LAR to read and speak the English language.
  • Positive PCR or antibody test within 12 months of initial study visit.
  • Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.

Exclusion criteria

  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.

Control Cohort -

Inclusion criteria

  • Ability to give informed consent
  • At least 18 years old
  • Ability of subject to read and speak the English language

Exclusion criteria

  • Known case of COVID-19.
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.

COVID-19 Control Cohort

Inclusion criteria

  • Ability to give informed consent.
  • At least 18 years old.
  • Ability of subject to read and speak the English language.
  • Known case of COVID-19.

Exclusion criteria

  • Known Longhauler's syndrome/Post-COVID
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.

Treatment and study plan

Primary outcomes

  1. Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors

    Time frame: 6 months

    If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
May 26, 2021
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.